Updated Date: Tue, 21 Feb 2023 00:00:00 EST
Phase 2 study of OK-101 will commence soon as company hopes drug will provide unmet need
If approved company’s prostate cancer therapy will be the first dual-action tablet available in EU
Tech was created to overcome adoption obstacles currently reducing the use of predictive human liver models
Updated Date: Fri, 17 Feb 2023 00:00:00 EST
Updated Date: Fri, 17 Feb 2023 00:00:00 EST
Updated Date: Fri, 17 Feb 2023 00:00:00 EST
Updated Date: Fri, 17 Feb 2023 00:00:00 EST
Updated Date: Fri, 17 Feb 2023 00:00:00 EST
